(ORLANDO, Fla.) Hesperos, Inc. has announced that it has been named one of the 50 statewide companies expected to see significant growth over the next several years by GrowFL. The 50 companies were selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association … Read more
ORLANDO, FLA – September 6, 2018 — Hesperos, Inc. announced today the receipt of a $4 million three-year NIH Phase IIb Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to increase capacity for its novel human-on-a-chip technology, and prepare its systems for regulatory … Read more
Hesperos, Inc., announced today the receipt of a NIH Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) National Institute on Aging (NIA) to help create a new multi-organ “human-on-a-chip” model that can realistically mimic the biology of Alzheimer’s Disease (AD) and the effects of potential new therapies under … Read more
Dr. Shuler’s “UniChip enables long-term recirculating unidirectional perfusion with gravity-driven flow for microphysiological systems” has been selected by the handling Editor as one of the top 10% of papers published in Lab on a Chip. This selection is based on the exceptionally positive referee reports that the manuscript received during peer review, along with the Editor’s … Read more
(ORLANDO, Fla.) Hesperos, Inc. has announced that it is among the first round of finalists for the 2018 Florida Companies to Watch honor, recently announced by GrowFL. The awards event – now in its eighth year – honors 50 select second-stage companies from throughout the state for developing valuable products and services, creating quality jobs, enriching communities, … Read more
ORLANDO, FLA – April 25, 2018 — Hesperos, Inc. has increased its pioneering human-on-a-chip drug testing capabilities by adding a new in vitro, human-human neuromuscular model to its patented multi-organ microfluidic device systems. Abnormal function of the neuromuscular junction is associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, and … Read more
Getting drugs past the neuroprotective blood-brain barrier (BBB) has been a perplexing problem and formidable challenge for researchers and pharmaceutical companies alike. Hesperos’s creation of a microfluidic model capable of mimicking in vivo characteristics of the blood-brain barrier for prolonged periods was therefore widely welcomed, and recently earned CEO Michael L. Shuler recognition from the American … Read more
The challenge: Build microfluidic devices that can keep cells alive in a setting that mimics specific organs or tissues, and incorporate biosensors to measure the cells’ physiology. The goal: Mimic diseases and test drug responses that traditional 2D culture systems and animal models have been unable to predict, filling a critical gap in drug development … Read more
For the second year in a row, SLAS Technology has chosen the article “TEER Measurement Techniques for In Vitro Barrier Model Systems”, co-authored by Dr. Hickman and Dr. Shuler, for the 2018 SLAS Technology Authors Choice Award. This award reflecting the article’s high impact and visibility throughout the 2017 year.
Hesperos President Dr. Mike Shuler has won the 2018 Biotechnology and Bioengineering Gaden Award! The Gaden Award is named in honor of Elmer L. Gaden, Jr., the founding editor of Biotechnology & Bioengineering, and is given in recognition of a truly outstanding paper published in the journal during the last year. The paper selected for … Read more